There are implementation challenges, but “the sooner clinicians get on the bandwagon, the better it will be for patient care,” one expert says.

The analysis reflects the consistent application of effective tools for CVD risk factor control and acute MI care, say the researchers.

The underpowered trial won’t change things for some proponents of radial PCI, but other operators were reassured and relieved by the results.

The findings could “change the paradigm” of post-PCI antiplatelet therapy choices in noncomplex patients, experts say.

“Adding physiology to the anatomy is going to be an approach that we’re predominately using in the future,” Matthew Budoff says.

For many interventional cardiologists, the findings translate into them getting up less in the middle of the night for emergency catheterizations.

These practice-changing results allow more flexibility for patients and physicians, relieving the burden of crowded EDs, one observer says.

The study found a survival advantage that favored oral treatment, possible due to early discharge and avoidance of hospital-related harms.

It’s too early to make any treatment recommendations, but the issue is worth keeping an eye on, experts agree.

Day 2 was jam-packed with more TAVR plus COAPT, AUGUSTUS, and beyond. Today promises antihypertensives, lipid-lowering, DAPT, omega-3s and more.